Kiwi, Seriously?
____________________________________________________________________
Quote:
Oslo, Norway, 24 August 2012: Pronova BioPharma (OSE: PRON.OL) yesterday received notice that the Spanish Ministry of Health has decided, as part of a general measure to reduce healthcare expenditure, to discontinue reimbursement of Omacor with effect from 1 September. Pronova BioPharma and Grupo Ferrer, who holds the exclusive license to Omacor in Spain, object to the decision and are considering various actions to secure continued good access to Omacor for Spanish patients.
_________________________________________________________________
That's convenient. Where's the rest of their conclusions about the science? Upon further review, they likely found the effects "Unremarkable".
Following the landmark Reduce-it trial results, the EMA equivilent of our Medical Society of Cardiology, remmended the removal of Omacor from it's Stand of Care Guidance. They replaced the guidance with Icospant Ethyl 4g daily.
ILT
Following the release of the Reduce-it results, in 2019, the EMA equivilent of our Medical Society of Cardiology, recommeded Omacor removed from it's standard of Care guidelance, and list in it's place, Icosapent Ethyl as the new Standard of Care.